New Haven’s Biohaven Pharmaceuticals has enrolled the first patients in a first-of-its kind clinical trial led by Massachusetts General Hospital for patients with amyotrophic lateral sclerosis (ALS).
Biohaven’s experimental drug verdiperstat was selected last September as one of the first three candidates to be tested in the so-called platform trial.